Unfortunately, cell lines with endogenous activating ER mutations are rare, limiting the ability to test in vivo. Patient derived xenograft (PDX) breast cancer models harboring ER mutations have recently been reported, and are useful tools for preclinical discovery. Here, ESR1 is linked to breast cancer.